BYND Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Beyond Meat is not a good buy right now for a beginner long-term investor with $50,000-$100,000 available. The stock is trading near penny-stock levels, the trend is still weak, analyst sentiment is broadly negative, insider selling is elevated, and the business is showing ongoing revenue and volume declines with no clear turnaround. The recent price bounce does not change the overall bearish setup. For an impatient investor who does not want to wait for a better entry, this is still a sell rather than a buy.
BYND shows a bearish technical structure. MACD histogram is negative at -0.00858 and remains below zero, RSI_6 is 40.314, which is neutral but not bullish, and the moving averages are bearish with SMA_200 > SMA_20 > SMA_5. Current price at 0.7109 is below the pivot at 0.743 and only slightly above support at 0.679, which means upside momentum is weak and price remains vulnerable. The short-term stock trend model suggests only modest next-day upside but negative weekly performance, which does not support a strong entry.
Potential positives are limited: the company launched its Beyond Immerse protein drink line, which offers a new product direction, and the stock has shown occasional short-term bounce potential based on pattern analysis. Options activity also leans toward calls, which may indicate speculative bullish positioning. The most recent session closed slightly higher than the prior close.
Recent catalysts are mainly negative: Q1 net revenue declined 15% to about $58 million and missed expectations, product volume fell nearly 20%, 2025 revenue declined 16% to $275 million, and operating losses widened to $333 million. Management guided Q1 sales down another 14% to 17%, suggesting no near-term recovery. Competition in plant-based foods and beverages remains intense, and insider selling has increased sharply over the last month.
Latest quarter: Q1 2026. Revenue fell 15% year over year to roughly $58 million, missing estimates. Volume dropped nearly 20%, showing continued demand weakness. Although the net loss narrowed to $46.8 million, the business is still deeply unprofitable. The broader recent trend is also poor, with 2025 revenue down 16% year over year to $275 million and operating losses reaching $333 million. Growth is negative and the latest quarter did not show a recovery trend.
Wall Street sentiment is bearish. TD Cowen cut its target to 60 cents and kept Sell, Mizuho cut to 50 cents and kept Underperform, Barclays cut to 50 cents and kept Underweight, and Jefferies cut to 70 cents with Hold. BMO also lowered its target to $1 and kept Market Perform. The overall pros view is that management is trying to reposition the brand and launch new products, but the cons view dominates: weak category demand, falling sales, margin pressure, and limited visibility. There is no recent politician or influential figure trading data, and no congress trading activity was reported.
